. Author manuscript; available in PMC: 2020 Jun 1.

Published in final edited form as: Am Heart J. 2019 Mar 4;212:1–12. doi: 10.1016/j.ahj.2019.02.011

Table I.

Statin studies using change in coronary plaque volume on Serial CCTA as a measure of therapeutic efficacy

Study	Population	Design	Therapy or Comparison	Main Finding
Inoue K et al. JACC Cardiovasc Imaging. 2010⁴⁸	Non-HIV with CAD, n=32	Prospective Interventional, not randomized	12 months fluvastatin vs refused fluvastatin	Mean plaque volume: Fluvastatin −15.9 mm³ vs control 4 mm³ (p=0.01)
Lo J et al. Lancet HIV. 2015²¹	PWH, n=37	Prospective Interventional Randomized Controlled	12 months atorvastatin vs placebo in persons with HIV	Median Δ noncalcified plaque volume: atorvastatin −19% (−8.2 mm3) vs. placebo +20% (+6.7 mm3), p=0.009
Auscher S et al. Atherosclerosis. 2015⁴⁹	HIV-uninfected with acute MI, n=96	Prospective Interventional Randomized Controlled	12 months intensive rosuvastatin vs standard statin	Median Δ plaque volume intensive: +43.5 vs standard: +19.1 mm3, p<0.001
Noguchi T et al. JACC 2015⁵⁰	HIV-uninfected CAD	Prospective. Interventional, non-randomized	12 months intensive pitavastatin vs propensity matched controls	Mean Δ low attenuation plaque volume: intensive −12.8 vs controls: +8.3 mm3, p=0.004

Abbreviations: CCTA, Coronary computed tomography angiography; CAD, coronary artery disease; PWH, people with HIV; Mi, myocardial infarction.